Notice: This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends VTL vs. LXRX, NKTR, CRBP, HURA, SGMT, DRUG, ACTU, GLSI, TSVT, and CKPTShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include Lexicon Pharmaceuticals (LXRX), Nektar Therapeutics (NKTR), Corbus Pharmaceuticals (CRBP), TuHURA Biosciences (HURA), Sagimet Biosciences (SGMT), Bright Minds Biosciences (DRUG), Actuate Therapeutics (ACTU), Greenwich LifeSciences (GLSI), 2seventy bio (TSVT), and Checkpoint Therapeutics (CKPT). These companies are all part of the "medical" sector. Vital Therapies vs. Lexicon Pharmaceuticals Nektar Therapeutics Corbus Pharmaceuticals TuHURA Biosciences Sagimet Biosciences Bright Minds Biosciences Actuate Therapeutics Greenwich LifeSciences 2seventy bio Checkpoint Therapeutics Vital Therapies (NASDAQ:VTL) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Does the media refer more to VTL or LXRX? In the previous week, Lexicon Pharmaceuticals had 7 more articles in the media than Vital Therapies. MarketBeat recorded 7 mentions for Lexicon Pharmaceuticals and 0 mentions for Vital Therapies. Lexicon Pharmaceuticals' average media sentiment score of 0.00 beat Vital Therapies' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Vital Therapies Neutral Lexicon Pharmaceuticals Neutral Is VTL or LXRX more profitable? Vital Therapies has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Lexicon Pharmaceuticals' return on equity of -107.38% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% Lexicon Pharmaceuticals -4,109.41%-107.38%-64.09% Which has more risk & volatility, VTL or LXRX? Vital Therapies has a beta of 3.51, meaning that its stock price is 251% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Does the MarketBeat Community favor VTL or LXRX? Lexicon Pharmaceuticals received 111 more outperform votes than Vital Therapies when rated by MarketBeat users. However, 74.40% of users gave Vital Therapies an outperform vote while only 64.78% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVital TherapiesOutperform Votes36974.40% Underperform Votes12725.60% Lexicon PharmaceuticalsOutperform Votes48064.78% Underperform Votes26135.22% Which has preferable valuation and earnings, VTL or LXRX? Vital Therapies has higher earnings, but lower revenue than Lexicon Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/ALexicon Pharmaceuticals$5.23M33.66-$177.12M-$0.75-0.95 Do insiders & institutionals have more ownership in VTL or LXRX? 15.5% of Vital Therapies shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 33.9% of Vital Therapies shares are owned by company insiders. Comparatively, 6.8% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend VTL or LXRX? Lexicon Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 739.51%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Vital Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vital Therapies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lexicon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryLexicon Pharmaceuticals beats Vital Therapies on 10 of the 15 factors compared between the two stocks. Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.37M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book3.455.094.784.78Net Income-$41.47M$151.83M$120.31M$225.60M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$1.00-3.8%N/A-28.6%$42.37MN/A0.0010LXRXLexicon Pharmaceuticals1.8046 of 5 stars$0.77-5.0%$6.00+679.3%-43.7%$189.58M$5.23M-1.08285News CoverageNKTRNektar Therapeutics4.4449 of 5 stars$1.00-1.0%$4.10+310.0%+96.7%$184.46M$93.14M-1.20220News CoverageGap UpCRBPCorbus Pharmaceuticals3.7007 of 5 stars$14.42-4.4%$62.00+330.0%+144.8%$175.64M$880,000.00-3.2240HURATuHURA BiosciencesN/A$4.14-16.0%$15.00+262.3%N/A$175.06MN/A0.00N/AAnalyst ForecastNews CoverageSGMTSagimet Biosciences2.3194 of 5 stars$5.68+29.4%$23.00+304.9%-12.2%$174.21M$2M0.008Gap UpHigh Trading VolumeDRUGBright Minds Biosciences3.5862 of 5 stars$39.05-4.8%$75.00+92.1%+2,587.2%$173.15MN/A-60.29N/ANews CoverageACTUActuate TherapeuticsN/A$8.69+0.8%N/AN/A$169.73MN/A0.0010Gap UpGLSIGreenwich LifeSciences1.3008 of 5 stars$12.90-4.5%$38.00+194.6%+13.9%$169.57MN/A-16.893TSVT2seventy bio2.2126 of 5 stars$3.26-0.3%$9.00+176.1%-18.4%$168.18M$100.39M-1.76440Positive NewsCKPTCheckpoint Therapeutics3.8249 of 5 stars$3.39-7.6%$10.33+204.8%+103.8%$165.53M$100,000.00-1.8310Insider TradeNews CoverageGap UpHigh Trading Volume Related Companies and Tools Related Companies LXRX Competitors NKTR Competitors CRBP Competitors HURA Competitors SGMT Competitors DRUG Competitors ACTU Competitors GLSI Competitors TSVT Competitors CKPT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
